The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
cSCC is one of the most common cancers in the U.S. and globally
The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product
The system, called GeneAgent, cross-checks its own initial predictions for accuracy against information from established, expert-curated databases
The facility includes advanced laboratories to monitor market trends, consumer needs, product innovation, and formulation improvements
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
The Genexus platform enables Next-Generation Sequencing with significantly faster turnaround times
Roche also shared the design of its upcoming Phase III TRONTIER 1 and 2 trials investigating trontinemab in people with early symptomatic Alzheimer’s disease
For patients with resectable early-stage gastric and gastroesophageal junction cancers
Subscribe To Our Newsletter & Stay Updated
